Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 19, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 19, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 240 Common Stock at $522.49 ($125,397) on August 19, 2026; holds 333,703 after (Indirect).
  • Open-market sale: disposed of 1,264 Common Stock at $523.65 ($661,888) on August 19, 2026; holds 332,439 after (Indirect).
  • Open-market sale: disposed of 441 Common Stock at $524.51 ($231,309) on August 19, 2026; holds 331,998 after (Indirect).
  • Open-market sale: disposed of 895 Common Stock at $525.60 ($470,409) on August 19, 2026; holds 331,103 after (Indirect).
  • Open-market sale: disposed of 2,105 Common Stock at $526.76 ($1,108,837) on August 19, 2026; holds 328,998 after (Indirect).
  • Open-market sale: disposed of 2,135 Common Stock at $527.58 ($1,126,375) on August 19, 2026; holds 326,863 after (Indirect).
  • Open-market sale: disposed of 1,200 Common Stock at $528.59 ($634,305) on August 19, 2026; holds 325,663 after (Indirect).
  • Open-market sale: disposed of 659 Common Stock at $529.56 ($348,979) on August 19, 2026; holds 325,004 after (Indirect).
  • Open-market sale: disposed of 201 Common Stock at $531.01 ($106,732) on August 19, 2026; holds 324,803 after (Indirect).
  • Open-market sale: disposed of 80 Common Stock at $531.62 ($42,530) on August 19, 2026; holds 324,723 after (Indirect).
  • Open-market sale: disposed of 200 Common Stock at $532.63 ($106,526) on August 19, 2026; holds 324,523 after (Indirect).
  • Open-market sale: disposed of 80 Common Stock at $535.22 ($42,817) on August 19, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on August 19, 2026; holds 103,910 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,006,104 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-19Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-08-19Open-market saleCommon Stock240$522$125.4K333,703
2026-08-19Open-market saleCommon Stock1,264$524$661.9K332,439
2026-08-19Open-market saleCommon Stock441$525$231.3K331,998
2026-08-19Open-market saleCommon Stock895$526$470.4K331,103
2026-08-19Open-market saleCommon Stock2,105$527$1.1M328,998
2026-08-19Open-market saleCommon Stock2,135$528$1.1M326,863
2026-08-19Open-market saleCommon Stock1,200$529$634.3K325,663
2026-08-19Open-market saleCommon Stock659$530$349.0K325,004
2026-08-19Open-market saleCommon Stock201$531$106.7K324,803
2026-08-19Open-market saleCommon Stock80$532$42.5K324,723
2026-08-19Open-market saleCommon Stock200$533$106.5K324,523
2026-08-19Open-market saleCommon Stock80$535$42.8K324,443
2026-08-19Option exercise/conversionStock Option9,500——103,910

Key Dates

DateDescription
2026-08-19Option exercise/conversion (9,500 shares)
2026-08-19Open-market sale (240 shares)
2026-08-19Open-market sale (1,264 shares)
2026-08-19Open-market sale (441 shares)
2026-08-19Open-market sale (895 shares)
2026-08-19Open-market sale (2,105 shares)
2026-08-19Open-market sale (2,135 shares)
2026-08-19Open-market sale (1,200 shares)
2026-08-19Open-market sale (659 shares)
2026-08-19Open-market sale (201 shares)
2026-08-19Open-market sale (80 shares)
2026-08-19Open-market sale (200 shares)
2026-08-19Open-market sale (80 shares)
2026-08-19Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.